|
EP2284269B1
(en)
|
2002-11-18 |
2017-08-09 |
Roche Innovation Center Copenhagen A/S |
Antisense design
|
|
CA2740785C
(en)
|
2008-10-15 |
2017-06-20 |
Isis Pharmaceuticals, Inc. |
Modulation of factor 11 expression
|
|
BRPI0923225A2
(pt)
|
2008-12-02 |
2016-10-04 |
Chiralgen Ltd |
metodo para sintese de acidos nucleicos modificados no atomo de fosforo
|
|
EP2451461A4
(en)
|
2009-07-06 |
2013-05-29 |
Ontorii Inc |
NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
|
|
DK2620428T3
(da)
|
2010-09-24 |
2019-07-01 |
Wave Life Sciences Ltd |
Asymmetrisk hjælpegruppe
|
|
EP3521451A1
(en)
|
2010-11-17 |
2019-08-07 |
Ionis Pharmaceuticals, Inc. |
Modulation of alpha synuclein expression
|
|
CN107365339A
(zh)
|
2011-07-19 |
2017-11-21 |
波涛生命科学有限公司 |
合成官能化核酸的方法
|
|
HK1200484A1
(zh)
|
2011-09-14 |
2015-08-07 |
Translate Bio Ma, Inc. |
多聚寡核苷酸化合物
|
|
CN104540946A
(zh)
|
2012-05-16 |
2015-04-22 |
Rana医疗有限公司 |
用于调节utrn表达的组合物和方法
|
|
EA201492120A1
(ru)
|
2012-05-16 |
2015-10-30 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии atp2a2
|
|
JP2015523854A
(ja)
|
2012-05-16 |
2015-08-20 |
ラナ セラピューティクス インコーポレイテッド |
Ｓｍｎ遺伝子ファミリー発現を調節するための組成物及び方法
|
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
|
US10174315B2
(en)
|
2012-05-16 |
2019-01-08 |
The General Hospital Corporation |
Compositions and methods for modulating hemoglobin gene family expression
|
|
CN104583402A
(zh)
|
2012-05-16 |
2015-04-29 |
Rana医疗有限公司 |
用于调节mecp2表达的组合物和方法
|
|
DK2872147T3
(da)
|
2012-07-13 |
2023-02-20 |
Wave Life Sciences Ltd |
Fremgangsmåde til fremstilling af kirale oligonukleotider
|
|
WO2014010250A1
(en)
|
2012-07-13 |
2014-01-16 |
Chiralgen, Ltd. |
Asymmetric auxiliary group
|
|
US20150247141A1
(en)
|
2012-09-14 |
2015-09-03 |
Rana Therapeutics, Inc. |
Multimeric oligonucleotide compounds
|
|
CA2889044A1
(en)
|
2012-11-15 |
2014-05-22 |
Roche Innovation Center Copenhagen A/S |
Anti apob antisense conjugate compounds
|
|
CA2893801A1
(en)
*
|
2013-01-30 |
2014-08-07 |
F. Hoffmann-La Roche Ag |
Lna oligonucleotide carbohydrate conjugates
|
|
JP2016518842A
(ja)
|
2013-05-01 |
2016-06-30 |
レグルス セラピューティクス インコーポレイテッド |
マイクロＲＮＡ化合物およびｍｉＲ−１２２をモジュレートする方法
|
|
EP2992096B1
(en)
|
2013-05-01 |
2021-03-03 |
Regulus Therapeutics Inc. |
Compounds and methods for enhanced cellular uptake
|
|
PL2992098T3
(pl)
|
2013-05-01 |
2019-09-30 |
Ionis Pharmaceuticals, Inc. |
Kompozycje i sposoby modulowania ekspresji hbv i ttr
|
|
US9943604B2
(en)
|
2013-09-20 |
2018-04-17 |
Ionis Pharmaceuticals, Inc. |
Targeted therapeutic nucleosides and their use
|
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
|
WO2015061536A1
(en)
|
2013-10-25 |
2015-04-30 |
Regulus Therapeutics Inc. |
Microrna compounds and methods for modulating mir-21 activity
|
|
EP3095461A4
(en)
|
2014-01-15 |
2017-08-23 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
|
|
EP3095459A4
(en)
|
2014-01-15 |
2017-08-23 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
|
|
EP3094728B1
(en)
|
2014-01-16 |
2022-03-09 |
Wave Life Sciences Ltd. |
Chiral design
|
|
US10358643B2
(en)
|
2014-01-30 |
2019-07-23 |
Hoffmann-La Roche, Inc. |
Poly oligomer compound with biocleavable conjugates
|
|
SI3119888T1
(sl)
|
2014-03-19 |
2021-11-30 |
Ionis Pharmaceuticals, Inc. |
Sestavki za moduliranje izražanja ataksina 2
|
|
WO2015143245A1
(en)
|
2014-03-19 |
2015-09-24 |
Isis Pharmaceuticals, Inc. |
Methods for modulating ataxin 2 expression
|
|
HUE050704T2
(hu)
|
2014-04-01 |
2020-12-28 |
Biogen Ma Inc |
Összetételek a SOD-1 expressziójának modulálására
|
|
CR20160554A
(es)
|
2014-05-01 |
2017-03-07 |
Ionis Pharmaceuticals Inc |
Composiciones y métodos para modular la expresión del factor b del complemento
|
|
WO2015168618A2
(en)
|
2014-05-01 |
2015-11-05 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating growth hormone receptor expression
|
|
WO2015168589A2
(en)
|
2014-05-01 |
2015-11-05 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating angiopoietin-like 3 expression
|
|
HUE052709T2
(hu)
|
2014-05-01 |
2021-05-28 |
Ionis Pharmaceuticals Inc |
Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására
|
|
GB201408623D0
(en)
|
2014-05-15 |
2014-07-02 |
Santaris Pharma As |
Oligomers and oligomer conjugates
|
|
MA40463A
(fr)
*
|
2014-08-07 |
2017-06-14 |
Regulus Therapeutics Inc |
Ciblage de micro-arn pour traiter des troubles métaboliques
|
|
WO2016040748A1
(en)
|
2014-09-12 |
2016-03-17 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for detection of smn protein in a subject and treatment of a subject
|
|
AU2015329974B2
(en)
|
2014-10-10 |
2019-06-20 |
F. Hoffmann-La Roche Ag |
GaINAc phosphoramidites, nucleic acid conjugates thereof and their use
|
|
US10308937B2
(en)
*
|
2014-11-10 |
2019-06-04 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Combination long acting compositions and methods for Hepatitis C
|
|
DK3234131T3
(da)
|
2014-12-16 |
2020-06-29 |
Roche Innovation Ct Copenhagen As |
Fremgangsmåde til screening af kiral toksicitet
|
|
AU2015367378A1
(en)
|
2014-12-17 |
2017-06-15 |
Proqr Therapeutics Ii B.V. |
Targeted RNA editing
|
|
US20170369872A1
(en)
|
2014-12-18 |
2017-12-28 |
Alnylam Pharmaceuticals, Inc. |
Reversir tm compounds
|
|
US10793855B2
(en)
|
2015-01-06 |
2020-10-06 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
|
US10538763B2
(en)
|
2015-01-16 |
2020-01-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of DUX4
|
|
WO2016130943A1
(en)
*
|
2015-02-13 |
2016-08-18 |
Rana Therapeutics, Inc. |
Hybrid oligonucleotides and uses thereof
|
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
|
CN107429250B
(zh)
|
2015-04-03 |
2022-03-01 |
Ionis制药公司 |
用于调节tmprss6表达的化合物和方法
|
|
EP3929293A3
(en)
|
2015-04-03 |
2022-03-16 |
University Of Massachusetts |
Fully stabilized asymmetric sirna
|
|
WO2016161378A1
(en)
|
2015-04-03 |
2016-10-06 |
University Of Massachusetts |
Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
|
|
RS60762B1
(sr)
|
2015-04-03 |
2020-10-30 |
Univ Massachusetts |
Oligonukleotidna jedinjenja za ciljane irnk hantingtina
|
|
WO2016167780A1
(en)
|
2015-04-16 |
2016-10-20 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
|
WO2017030973A1
(en)
|
2015-08-14 |
2017-02-23 |
University Of Massachusetts |
Bioactive conjugates for oligonucleotide delivery
|
|
KR20180043819A
(ko)
|
2015-08-24 |
2018-04-30 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
Lna-g 방법
|
|
EP3353305A4
(en)
*
|
2015-09-25 |
2019-09-18 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
WO2017055423A1
(en)
|
2015-10-02 |
2017-04-06 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide conjugation process
|
|
MA46427A
(fr)
|
2015-10-09 |
2018-08-15 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
|
WO2017068087A1
(en)
|
2015-10-22 |
2017-04-27 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide detection method
|
|
AU2016349625B2
(en)
|
2015-11-06 |
2022-07-07 |
Ionis Pharmaceuticals, Inc. |
Modulating apolipoprotein (a) expression
|
|
LT4119569T
(lt)
*
|
2015-11-06 |
2024-09-25 |
Ionis Pharmaceuticals, Inc. |
Konjuguoti priešprasmiai junginiai, skirti panaudoti terapijoje
|
|
HK1258434A1
(zh)
|
2015-11-12 |
2019-11-08 |
F. Hoffmann-La Roche Ag |
来自灵长类物种的标准化神经元细胞测定试验
|
|
EP3389670A4
(en)
|
2015-12-04 |
2020-01-08 |
Ionis Pharmaceuticals, Inc. |
METHODS OF TREATING BREAST CANCER
|
|
WO2017117496A1
(en)
|
2015-12-31 |
2017-07-06 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing ataxin-2 expression
|
|
EP3400300A4
(en)
|
2016-01-05 |
2019-08-07 |
Ionis Pharmaceuticals, Inc. |
PROCESS FOR REDUCING LRRK2 EXPRESSION
|
|
KR20180103166A
(ko)
*
|
2016-01-29 |
2018-09-18 |
교와 핫꼬 기린 가부시키가이샤 |
핵산 복합체
|
|
WO2017132669A1
(en)
|
2016-01-31 |
2017-08-03 |
University Of Massachusetts |
Branched oligonucleotides
|
|
JOP20170057B1
(ar)
|
2016-03-07 |
2022-03-14 |
Arrowhead Pharmaceuticals Inc |
مركبات ترابطية مستهدفة كمركبات علاجية
|
|
CA3013683C
(en)
|
2016-03-14 |
2021-07-13 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for reduction of pd-l1 expression
|
|
WO2017161168A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of dyrk1b expression
|
|
CA3013799A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Methods of modulating keap1
|
|
KR102775461B1
(ko)
*
|
2016-04-01 |
2025-02-28 |
어비디티 바이오사이언시스 인크. |
핵산-폴리펩타이드 조성물 및 이의 용도
|
|
EP3228326A1
(en)
*
|
2016-04-05 |
2017-10-11 |
Silence Therapeutics GmbH |
Nucleic acid linked to a trivalent glycoconjugate
|
|
AU2017248189B2
(en)
*
|
2016-04-08 |
2021-04-29 |
Translate Bio, Inc. |
Multimeric coding nucleic acid and uses thereof
|
|
WO2017178656A1
(en)
|
2016-04-14 |
2017-10-19 |
Roche Innovation Center Copenhagen A/S |
TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE
|
|
CN109475568B
(zh)
|
2016-05-06 |
2026-07-17 |
Ionis制药公司 |
Glp-1受体配体部分缀合的寡核苷酸及其用途
|
|
AU2017286811A1
(en)
|
2016-06-17 |
2018-11-22 |
Ionis Pharmaceuticals, Inc. |
Modulation of gys1 expression
|
|
AU2017285350A1
(en)
|
2016-06-17 |
2018-12-20 |
F. Hoffmann-La Roche Ag |
Nucleic acid molecules for reduction of PAPD5 or PAPD7 mRNA for treating hepatitis B infection
|
|
EP3475424A1
(en)
|
2016-06-22 |
2019-05-01 |
ProQR Therapeutics II B.V. |
Single-stranded rna-editing oligonucleotides
|
|
RU2019101298A
(ru)
|
2016-07-01 |
2020-08-03 |
Ф. Хоффманн-Ля Рош Аг |
Антисмысловые олигонуклеотиды для модулирования экспрессии htra1
|
|
WO2018031933A2
(en)
|
2016-08-12 |
2018-02-15 |
University Of Massachusetts |
Conjugated oligonucleotides
|
|
WO2018041973A1
(en)
|
2016-09-01 |
2018-03-08 |
Proqr Therapeutics Ii B.V. |
Chemically modified single-stranded rna-editing oligonucleotides
|
|
JOP20170056B1
(ar)
|
2016-09-02 |
2021-08-17 |
Arrowhead Pharmaceuticals Inc |
مركبات ترابطية مستهدفة
|
|
WO2018067900A1
(en)
|
2016-10-06 |
2018-04-12 |
Ionis Pharmaceuticals, Inc. |
Method of conjugating oligomeric compounds
|
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
|
US11033570B2
(en)
|
2016-12-02 |
2021-06-15 |
Cold Spring Harbor Laboratory |
Modulation of Lnc05 expression
|
|
EP3568479A1
(en)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb1 expression
|
|
WO2018130581A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rela expression
|
|
WO2018130584A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb2 expression
|
|
US20190345496A1
(en)
|
2017-01-13 |
2019-11-14 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating relb expression
|
|
EP3568478A1
(en)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rel expression
|
|
WO2018165541A1
(en)
*
|
2017-03-10 |
2018-09-13 |
The Board Of Regents Of The University Of Texas System |
Treatment of fuchs' endothelial corneal dystrophy
|
|
JP7048574B2
(ja)
|
2017-03-10 |
2022-04-05 |
国立研究開発法人国立成育医療研究センター |
アンチセンスオリゴヌクレオチドおよび糖原病Ｉａ型予防または治療用組成物
|
|
CA3059426A1
(en)
|
2017-04-11 |
2018-10-18 |
Arbutus Biopharma Corporation |
Targeted compositions
|
|
WO2018215049A1
(en)
*
|
2017-05-23 |
2018-11-29 |
F. Hoffmann-La Roche Ag |
Process for galnac oligonucleotide conjugates
|
|
US11273222B2
(en)
|
2017-05-26 |
2022-03-15 |
National Cerebral And Cardiovascular Center |
Antisense nucleic acid targeting PCSK9
|
|
US20190055564A1
(en)
|
2017-06-01 |
2019-02-21 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for modulating htra1 expression
|
|
CN111164091B
(zh)
*
|
2017-06-02 |
2025-01-07 |
波涛生命科学有限公司 |
寡核苷酸组合物及其使用方法
|
|
US11401519B2
(en)
|
2017-06-07 |
2022-08-02 |
University Of Massachusetts |
Anti-ADAM33 oligonucleotides and related methods
|
|
WO2018237245A1
(en)
|
2017-06-23 |
2018-12-27 |
University Of Massachusetts |
TWO TAIL SELF-ADMINISTRATION SIRNA AND ASSOCIATED METHODS
|
|
TW201919712A
(zh)
|
2017-08-10 |
2019-06-01 |
法商塞勒尼斯醫療控股公司 |
運送子(cargomers)
|
|
WO2019030313A2
(en)
|
2017-08-11 |
2019-02-14 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF UBE3C EXPRESSION
|
|
EP3668981A4
(en)
|
2017-08-17 |
2021-05-26 |
Alnylam Pharmaceuticals, Inc. |
TUNED REVERSIR-TM CONNECTIONS
|
|
CA3071033A1
(en)
|
2017-08-18 |
2019-02-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of the notch signaling pathway for treatment of respiratory disorders
|
|
WO2019038228A1
(en)
|
2017-08-22 |
2019-02-28 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION
|
|
US10517889B2
(en)
|
2017-09-08 |
2019-12-31 |
Ionis Pharmaceuticals, Inc. |
Modulators of SMAD7 expression
|
|
EP3694530A4
(en)
*
|
2017-10-12 |
2021-06-30 |
Wave Life Sciences Ltd. |
COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
|
|
CN111226114A
(zh)
|
2017-10-13 |
2020-06-02 |
罗氏创新中心哥本哈根有限公司 |
用部分立体限定的寡核苷酸子文库鉴定反义寡核苷酸改进的立体限定硫代磷酸酯寡核苷酸变体的方法
|
|
KR20200030594A
(ko)
|
2017-10-16 |
2020-03-20 |
에프. 호프만-라 로슈 아게 |
B형 간염 감염을 치료하기 위한 PAPD5 및 PAPD7 mRNA의 감소용 핵산 분자
|
|
WO2019090359A1
(en)
|
2017-11-06 |
2019-05-09 |
Nitto Denko Corporation |
Fusogenic compounds for delivery of biologically active molecules
|
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
|
CN118291456A
(zh)
|
2017-12-01 |
2024-07-05 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
WO2019105414A1
(zh)
|
2017-12-01 |
2019-06-06 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
JP7360716B2
(ja)
|
2017-12-01 |
2023-10-13 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用
|
|
HRP20250277T1
(hr)
|
2017-12-01 |
2025-05-09 |
Suzhou Ribo Life Science Co., Ltd. |
Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba
|
|
CN110944675B9
(zh)
|
2017-12-01 |
2024-08-09 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
CN118638787A
(zh)
|
2017-12-06 |
2024-09-13 |
艾维迪提生物科学公司 |
治疗肌萎缩和强直性肌营养不良的组合物和方法
|
|
WO2019115416A2
(en)
|
2017-12-11 |
2019-06-20 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating fndc3b expression
|
|
WO2019115417A2
(en)
|
2017-12-12 |
2019-06-20 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating rb1 expression
|
|
WO2019126641A2
(en)
|
2017-12-21 |
2019-06-27 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
|
CA3085211A1
(en)
|
2017-12-21 |
2019-06-27 |
F. Hoffmann-La Roche Ag |
Companion diagnostic for htra1 rna antagonists
|
|
US20200339982A1
(en)
|
2017-12-22 |
2020-10-29 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorodithioate internucleoside linkage
|
|
CN111448316B
(zh)
|
2017-12-22 |
2025-02-14 |
罗氏创新中心哥本哈根有限公司 |
新的硫代亚磷酰胺
|
|
CN111448317B
(zh)
|
2017-12-22 |
2025-07-04 |
罗氏创新中心哥本哈根有限公司 |
包含二硫代磷酸酯核苷间键的缺口聚物寡核苷酸
|
|
CN110959011B
(zh)
*
|
2017-12-29 |
2023-03-28 |
苏州瑞博生物技术股份有限公司 |
缀合物及其制备方法和用途
|
|
CN111699258A
(zh)
|
2018-01-10 |
2020-09-22 |
哥本哈根罗氏创新中心 |
用于调控pias4表达的寡核苷酸
|
|
US20210095275A1
(en)
|
2018-01-12 |
2021-04-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating gsk3b expression
|
|
MY203356A
(en)
|
2018-01-12 |
2024-06-25 |
Bristol Myers Squibb Co |
Antisense oligonucleotides targeting alpha-synuclein and uses thereof
|
|
EP3737759A1
(en)
*
|
2018-01-12 |
2020-11-18 |
Roche Innovation Center Copenhagen A/S |
Alpha-synuclein antisense oligonucleotides and uses thereof
|
|
WO2019140236A1
(en)
|
2018-01-12 |
2019-07-18 |
Bristol-Myers Squibb Company |
Antisense oligonucleotides targeting alpha-synuclein and uses thereof
|
|
CA3088522A1
(en)
|
2018-01-15 |
2019-07-18 |
Ionis Pharmaceuticals, Inc. |
Modulators of dnm2 expression
|
|
WO2019141656A1
(en)
|
2018-01-17 |
2019-07-25 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating erc1 expression
|
|
EP3740573A1
(en)
|
2018-01-18 |
2020-11-25 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting srebp1
|
|
BR112020010436A2
(pt)
*
|
2018-01-26 |
2020-11-24 |
F. Hoffmann-La Roche Ag |
oligonucleotídeo radiomarcado, processos para a preparação de um oligonucleotídeo radiomarcado, uso do oligonucleotídeo radiomarcado, método para determinar a biodistribuição e farmacocinética e oligonucleotídeo
|
|
WO2019145386A1
(en)
|
2018-01-26 |
2019-08-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating csnk1d expression
|
|
BR112020016170A2
(pt)
|
2018-02-09 |
2020-12-15 |
Genentech, Inc. |
Oligonucleotídeos terapêutico e antissenso, conjugado, sal farmaceuticamente aceitável, composição farmacêutica, método in vitro ou in vivo para modular a expressão de tmem106b, método para tratar ou prevenir uma doença, uso do oligonucleotídeo e uso ou método
|
|
WO2019165067A1
(en)
|
2018-02-21 |
2019-08-29 |
Bristol-Myers Squibb Company |
Camk2d antisense oligonucleotides and uses thereof
|
|
WO2019165183A1
(en)
|
2018-02-22 |
2019-08-29 |
Entrada Therapeutics, Inc. |
Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
|
|
WO2019169243A1
(en)
|
2018-03-02 |
2019-09-06 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of amyloid-beta precursor protein
|
|
TWI840345B
(zh)
|
2018-03-02 |
2024-05-01 |
美商Ionis製藥公司 |
Irf4表現之調節劑
|
|
WO2019172286A1
(ja)
|
2018-03-09 |
2019-09-12 |
第一三共株式会社 |
糖原病Ｉａ型治療薬
|
|
WO2019183440A1
(en)
|
2018-03-22 |
2019-09-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating fmr1 expression
|
|
MA52661A
(fr)
|
2018-04-05 |
2021-02-17 |
Centre Leon Berard |
Utilisation d'inhibiteurs de fubp1 dans le traitement d'une infection par le virus de l'hépatite b
|
|
WO2019200172A1
(en)
|
2018-04-11 |
2019-10-17 |
Ionis Pharmaceuticals, Inc. |
Modulators of ezh2 expression
|
|
JP2021522815A
(ja)
|
2018-05-07 |
2021-09-02 |
ロシュ イノベーション センター コペンハーゲン エーエス |
超並列シーケンシングを用いるｌｎａオリゴヌクレオチド治療法の品質管理法
|
|
TWI854980B
(zh)
|
2018-05-08 |
2024-09-11 |
美商雷格勒斯治療公司 |
用於調節mir-122之微小rna化合物及方法
|
|
US20210371860A1
(en)
|
2018-05-08 |
2021-12-02 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating myh7 expression
|
|
IL277970B2
(en)
|
2018-05-09 |
2025-03-01 |
Ionis Pharmaceuticals Inc |
Oligomeric compounds comprising modified oligonucleotides and conjugated groups for use in the treatment of end-stage renal disease, chronic kidney disease and coronary artery disease
|
|
JP2021522800A
(ja)
|
2018-05-09 |
2021-09-02 |
アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
Ａｔｘｎ３発現を低減するための化合物及び方法
|
|
CA3098624A1
(en)
|
2018-05-11 |
2019-11-14 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
AU2019266550A1
(en)
*
|
2018-05-11 |
2020-11-26 |
Alpha Anomeric Sas |
Oligonucleotides conjugates comprising 7'-5'-alpha-anomeric-bicyclic sugar nucleosides
|
|
GB201808146D0
(en)
|
2018-05-18 |
2018-07-11 |
Proqr Therapeutics Ii Bv |
Stereospecific Linkages in RNA Editing Oligonucleotides
|
|
EP3802824A1
(en)
|
2018-06-05 |
2021-04-14 |
F. Hoffmann-La Roche AG |
Oligonucleotides for modulating atxn2 expression
|
|
CA3103429A1
(en)
|
2018-06-14 |
2019-12-19 |
Don W. Cleveland |
Compounds and methods for increasing stmn2 expression
|
|
TWI833770B
(zh)
|
2018-06-27 |
2024-03-01 |
美商Ionis製藥公司 |
用於減少 lrrk2 表現之化合物及方法
|
|
WO2020007702A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting bcl2l11
|
|
WO2020007700A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting spi1
|
|
WO2020007772A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting gbp-1
|
|
TWI862501B
(zh)
|
2018-07-03 |
2024-11-21 |
瑞士商赫孚孟拉羅股份公司 |
用於調制 Tau 表現之寡核苷酸
|
|
WO2020007889A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting stat1
|
|
WO2020007826A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mbtps1
|
|
WO2020011653A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting kynu
|
|
WO2020011743A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mafb
|
|
WO2020011869A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting tlr2
|
|
WO2020011744A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers5
|
|
WO2020011745A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers6
|
|
BR112021000538A2
(pt)
|
2018-07-13 |
2021-04-06 |
F. Hoffmann-La Roche Ag |
Oligonucleotídeos para modular a expressão de rtel1
|
|
WO2020018558A1
(en)
|
2018-07-17 |
2020-01-23 |
Aronora, Inc. |
Methods for safely reducing thrombopoietin
|
|
AU2019310097A1
(en)
|
2018-07-25 |
2021-02-04 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing ATXN2 expression
|
|
BR112021001756A2
(pt)
|
2018-07-31 |
2021-05-11 |
Roche Innovation Center Copenhagen A/S |
oligonucleotídeos, oligonucleotídeo gapmer, sal farmaceuticamente aceitável, conjugado, composição farmacêutica, usos de um oligonucleotídeo, método para o tratamento ou profilaxia de uma doença, processo para a fabricação de um oligonucleotídeo e invenção
|
|
CA3098267A1
(en)
*
|
2018-07-31 |
2020-02-06 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
|
|
BR112021002440A2
(pt)
|
2018-08-10 |
2021-05-04 |
University Of Massachusetts |
oligonucleotídeos modificados visando snps
|
|
WO2020038377A1
(zh)
|
2018-08-21 |
2020-02-27 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的药物组合物和缀合物及其用途
|
|
WO2020038973A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting sptlc1
|
|
WO2020041769A1
(en)
|
2018-08-23 |
2020-02-27 |
University Of Massachusetts |
O-methyl rich fully stabilized oligonucleotides
|
|
WO2020038976A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting usp8
|
|
EP3841220A1
(en)
|
2018-08-23 |
2021-06-30 |
Roche Innovation Center Copenhagen A/S |
Microrna-134 biomarker
|
|
WO2020038971A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting vcan
|
|
US20220160870A1
(en)
|
2018-08-28 |
2022-05-26 |
Roche Innovation Center Copenhagen A/S |
Neoantigen engineering using splice modulating compounds
|
|
EP3620519A1
(en)
|
2018-09-04 |
2020-03-11 |
F. Hoffmann-La Roche AG |
Use of isolated milk extracellular vesicles for delivering oligonucleotides orally
|
|
WO2020051398A1
(en)
*
|
2018-09-06 |
2020-03-12 |
Aptamir Therapeutics, Inc. |
Metabolic benefits of short mir-22 mirna antagomir therapies
|
|
JP7376952B2
(ja)
|
2018-09-30 |
2023-11-09 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
ｓｉＲＮＡ複合体及びその調製方法と使用
|
|
JP2022512877A
(ja)
|
2018-11-01 |
2022-02-07 |
エフ．ホフマン－ラ ロシュ アーゲー |
Ｔｉａ１を標的とするアンチセンスオリゴヌクレオチド
|
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
|
MX2021005758A
(es)
|
2018-11-15 |
2021-09-21 |
Ionis Pharmaceuticals Inc |
Moduladores de la expresión de irf5.
|
|
US12281305B2
(en)
|
2018-11-21 |
2025-04-22 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing prion expression
|
|
EP3894559A4
(en)
|
2018-12-03 |
2023-04-05 |
Triplet Therapeutics, Inc. |
METHODS OF TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS RELATED TO MLH3 ACTIVITY
|
|
JP2022515744A
(ja)
|
2018-12-20 |
2022-02-22 |
プラクシス プレシジョン メディシンズ， インコーポレイテッド |
Ｋｃｎｔ１関連障害の治療のための組成物及び方法
|
|
JP2022514648A
(ja)
|
2018-12-21 |
2022-02-14 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｃａｒｄ９を標的とするアンチセンスオリゴヌクレオチド
|
|
JP7507495B2
(ja)
|
2018-12-28 |
2024-06-28 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
|
|
CN113614232A
(zh)
*
|
2019-01-18 |
2021-11-05 |
马萨诸塞大学 |
动态药代动力学修饰锚
|
|
CN113365607A
(zh)
|
2019-01-25 |
2021-09-07 |
豪夫迈·罗氏有限公司 |
用于口服药物递送的脂质囊泡
|
|
TW202214854A
(zh)
|
2019-01-31 |
2022-04-16 |
美商Ionis製藥公司 |
Yap1表現之調節劑
|
|
WO2020169696A1
(en)
|
2019-02-20 |
2020-08-27 |
Roche Innovation Center Copenhagen A/S |
Novel phosphoramidites
|
|
MX2021009950A
(es)
|
2019-02-20 |
2021-09-21 |
Roche Innovation Ct Copenhagen As |
Oligonucleotidos gapmeros de fosfonoacetato.
|
|
JP7503072B2
(ja)
|
2019-02-26 |
2024-06-19 |
ロシュ イノベーション センター コペンハーゲン エーエス |
オリゴヌクレオチドの製剤化方法
|
|
WO2020176771A1
(en)
|
2019-02-27 |
2020-09-03 |
Ionis Pharmaceuticals, Inc. |
Modulators of malat1 expression
|
|
WO2020178258A1
(en)
*
|
2019-03-05 |
2020-09-10 |
F. Hoffmann-La Roche Ag |
Intracellular targeting of molecules
|
|
TW202536179A
(zh)
|
2019-03-29 |
2025-09-16 |
美商Ionis製藥公司 |
用於調節ube3a-ats之化合物及方法
|
|
US20220177894A1
(en)
|
2019-04-02 |
2022-06-09 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for immunotherapy
|
|
JP7725370B2
(ja)
|
2019-04-03 |
2025-08-19 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ａｎｇｐｔｌ２アンチセンスオリゴヌクレオチドおよびその使用
|
|
WO2020201339A1
(en)
|
2019-04-04 |
2020-10-08 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating atxn2 expression
|
|
US11286485B2
(en)
|
2019-04-04 |
2022-03-29 |
Hoffmann-La Roche Inc. |
Oligonucleotides for modulating ATXN2 expression
|
|
JP7610848B2
(ja)
|
2019-05-22 |
2025-01-09 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、薬物組成物及び複合体ならびに調製方法と使用
|
|
CN113286888B
(zh)
|
2019-05-22 |
2023-12-22 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
CN113227376B
(zh)
|
2019-05-22 |
2024-04-09 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
CN113795582B
(zh)
|
2019-05-24 |
2024-05-24 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
KR20220024192A
(ko)
|
2019-05-31 |
2022-03-03 |
알리고스 테라퓨틱스 인코포레이티드 |
변형된 갭머 올리고뉴클레오타이드 및 사용 방법
|
|
WO2020245233A1
(en)
|
2019-06-06 |
2020-12-10 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting atxn3
|
|
PL3956450T3
(pl)
|
2019-07-26 |
2025-12-22 |
Ionis Pharmaceuticals, Inc. |
Związki i sposoby modulowania gfap
|
|
US20230114023A1
(en)
*
|
2019-07-30 |
2023-04-13 |
Mpeg La, L.L.C. |
Subcutaneous delivery of multimeric oligonucleotides with enhanced bioactivity
|
|
KR20220047989A
(ko)
|
2019-08-09 |
2022-04-19 |
유니버시티 오브 매사추세츠 |
Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드
|
|
IL291251B2
(en)
|
2019-09-10 |
2026-06-01 |
Daiichi Sankyo Co Limited |
CONJUGATE OF GalNAC-OLIGONUCLEOTIDE FOR DELIVERY TO LIVER AND MANUFACTURING METHOD THEREOF
|
|
US12365894B2
(en)
|
2019-09-16 |
2025-07-22 |
University Of Massachusetts |
Branched lipid conjugates of siRNA for specific tissue delivery
|
|
AU2020356931A1
(en)
|
2019-10-02 |
2022-05-26 |
Sirnaomics, Inc. |
Oligonucleotides with nucleoside analogs
|
|
JP7634542B2
(ja)
|
2019-12-19 |
2025-02-21 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｂ型肝炎ウイルス感染症を処置するためのｓｅｐｔ９阻害剤の使用
|
|
JP2023506540A
(ja)
|
2019-12-19 |
2023-02-16 |
エフ． ホフマン－ラ ロシュ エージー． |
Ｂ型肝炎ウイルス感染を処置するためのｓｃａｍｐ３阻害剤の使用
|
|
EP4058032A4
(en)
*
|
2019-12-19 |
2024-01-10 |
Entrada Therapeutics, Inc. |
Compositions for delivery of antisense compounds
|
|
WO2021122910A1
(en)
|
2019-12-19 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Use of sbds inhibitors for treating hepatitis b virus infection
|
|
CN114867856A
(zh)
|
2019-12-19 |
2022-08-05 |
豪夫迈·罗氏有限公司 |
Saraf抑制剂用于治疗乙型肝炎病毒感染的用途
|
|
WO2021122921A1
(en)
|
2019-12-19 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Use of cops3 inhibitors for treating hepatitis b virus infection
|
|
WO2021123086A1
(en)
|
2019-12-20 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Enhanced oligonucleotides for inhibiting scn9a expression
|
|
EP4081639A1
(en)
|
2019-12-24 |
2022-11-02 |
F. Hoffmann-La Roche AG |
Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
|
|
EP4081217A1
(en)
|
2019-12-24 |
2022-11-02 |
F. Hoffmann-La Roche AG |
Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv
|
|
US20230090446A1
(en)
|
2020-01-28 |
2023-03-23 |
Universite De Strasbourg |
Antisense oligonucleotide targeting linc00518 for treating melanoma
|
|
WO2021158810A1
(en)
|
2020-02-05 |
2021-08-12 |
Bristol-Myers Squibb Company |
Oligonucleotides for splice modulation of camk2d
|
|
AU2021225957A1
(en)
|
2020-02-28 |
2022-09-08 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating SMN2
|
|
EP4110916A1
(en)
|
2020-02-28 |
2023-01-04 |
F. Hoffmann-La Roche AG |
Oligonucleotides for modulating cd73 exon 7 splicing
|
|
CA3174708A1
(en)
*
|
2020-03-04 |
2021-09-10 |
Verve Therapeutics, Inc. |
Compositions and methods for targeted rna delivery
|
|
TW202144572A
(zh)
|
2020-03-19 |
2021-12-01 |
美商亞維代堤生物科學公司 |
治療臉肩胛肱骨肌肉失養症之組合物及方法
|
|
EP4132951A4
(en)
|
2020-04-09 |
2025-06-11 |
Verve Therapeutics, Inc. |
CHEMICALLY MODIFIED GENE EDITING GUIDE RNAS WITH CAS12B
|
|
JP2023522957A
(ja)
*
|
2020-04-21 |
2023-06-01 |
フラッグシップ パイオニアリング， インコーポレイテッド |
二機能性分子およびその使用方法
|
|
TWI901676B
(zh)
|
2020-05-01 |
2025-10-21 |
美商Ionis製藥公司 |
調節ａｔｘｎ１之化合物及方法
|
|
CN115698290A
(zh)
|
2020-05-11 |
2023-02-03 |
基因泰克公司 |
用于治疗神经系统疾病的补体组分4抑制剂以及使用它们的相关组合物、系统和方法
|
|
CN115551519A
(zh)
|
2020-05-11 |
2022-12-30 |
基因泰克公司 |
用于治疗神经系统疾病的补体组分c1s抑制剂以及相关的组合物、系统和使用它们的方法
|
|
CN115605592A
(zh)
|
2020-05-11 |
2023-01-13 |
基因泰克公司（Us） |
用于治疗神经系统疾病的补体组分c1r抑制剂以及相关的组合物、系统和使用它们的方法
|
|
WO2021229036A1
(en)
|
2020-05-13 |
2021-11-18 |
F. Hoffmann-La Roche Ag |
Oligonucleotide agonists targeting progranulin
|
|
EP4150076A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
|
|
WO2021231691A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
|
|
EP4150086A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
|
WO2021231698A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
|
EP4150077A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
|
EP4150087A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
|
EP4150090A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
|
EP4150088A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
|
US20230193269A1
(en)
|
2020-05-22 |
2023-06-22 |
Boehringer Ingelheim International Gmbh |
Oligonucleotides for splice modulation of card9
|
|
CA3174079A1
(en)
|
2020-05-26 |
2021-12-02 |
Anastasia Khvorova |
Synthetic oligonucleotides having regions of block and cluster modifications
|
|
US11408000B2
(en)
|
2020-06-03 |
2022-08-09 |
Triplet Therapeutics, Inc. |
Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
|
|
EP4162047A1
(en)
|
2020-06-09 |
2023-04-12 |
Roche Innovation Center Copenhagen A/S |
Guanosine analogues for use in therapeutic polynucleotides
|
|
AR122731A1
(es)
|
2020-06-26 |
2022-10-05 |
Hoffmann La Roche |
Oligonucleótidos mejorados para modular la expresión de fubp1
|
|
TW202216996A
(zh)
|
2020-06-29 |
2022-05-01 |
美商Ionis製藥公司 |
調節ｐｌｐ１之化合物及方法
|
|
WO2022018155A1
(en)
|
2020-07-23 |
2022-01-27 |
F. Hoffmann-La Roche Ag |
Lna oligonucleotides for splice modulation of stmn2
|
|
EP4185696A1
(en)
|
2020-07-23 |
2023-05-31 |
F. Hoffmann-La Roche AG |
Oligonucleotides targeting rna binding protein sites
|
|
MX2023001222A
(es)
|
2020-07-28 |
2023-04-26 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para reducir la expresion de app.
|
|
CN111671913B
(zh)
*
|
2020-07-30 |
2022-02-08 |
四川大学 |
一种量子点-小核酸偶联物及其用途
|
|
IL300258A
(en)
|
2020-08-07 |
2023-03-01 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating SCN2A
|
|
JP2023538630A
(ja)
|
2020-08-21 |
2023-09-08 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｂ型肝炎ウイルス感染症を処置するためのａ１ｃｆ阻害剤の使用
|
|
CA3194161A1
(en)
*
|
2020-10-02 |
2022-04-07 |
David M. Evans |
Nucleoside containing sirnas for treating viral diseases
|
|
KR20230108728A
(ko)
|
2020-11-18 |
2023-07-18 |
아이오니스 파마수티컬즈, 인코포레이티드 |
앤지오텐시노겐 발현을 조절하기 위한 화합물 및 방법
|
|
TW202237843A
(zh)
|
2020-12-03 |
2022-10-01 |
瑞士商赫孚孟拉羅股份公司 |
靶向ａｔｘｎ３之反義寡核苷酸
|
|
WO2022117745A1
(en)
|
2020-12-03 |
2022-06-09 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting atxn3
|
|
AR124408A1
(es)
|
2020-12-18 |
2023-03-22 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para modular el factor xii
|
|
EP4263831A1
(en)
|
2020-12-18 |
2023-10-25 |
F. Hoffmann-La Roche AG |
Antisense oligonucleotides for targeting progranulin
|
|
CN116670282A
(zh)
|
2020-12-22 |
2023-08-29 |
豪夫迈·罗氏有限公司 |
靶向xbp1的寡核苷酸
|
|
CN114716518A
(zh)
*
|
2021-01-06 |
2022-07-08 |
圣诺制药公司 |
一种能够抑制pcsk9表达的分子构造及药物组合物
|
|
WO2022162015A1
(en)
|
2021-01-26 |
2022-08-04 |
Universite Brest Bretagne Occidentale |
Novel stim1 splicing variants and uses thereof
|
|
TW202246500A
(zh)
|
2021-02-02 |
2022-12-01 |
瑞士商赫孚孟拉羅股份公司 |
用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸
|
|
PE20240696A1
(es)
|
2021-03-08 |
2024-04-10 |
Servier Lab |
Oligonucleotidos antisentido para inhibir la expresion de la alfa-sinucleina
|
|
WO2022232650A1
(en)
*
|
2021-04-30 |
2022-11-03 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing agt expression
|
|
US20240263177A1
(en)
|
2021-05-20 |
2024-08-08 |
Korro Bio, Inc. |
Methods and Compositions for Adar-Mediated Editing
|
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
|
CA3222546A1
(en)
|
2021-06-08 |
2022-12-15 |
F. Hoffmann-La Roche Ag |
Oligonucleotide progranulin agonists
|
|
US12378267B2
(en)
|
2021-06-17 |
2025-08-05 |
Entrada Therapeutics, Inc. |
Synthesis of FMOC-protected morpholino monomers and oligomers
|
|
US11753644B2
(en)
|
2021-06-18 |
2023-09-12 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing IFNAR1 expression
|
|
IL309334A
(en)
|
2021-06-23 |
2024-02-01 |
Univ Massachusetts |
Anti-FLT1 optimized oligonucleotide compounds for the treatment of preeclampsia and other angiogenic disorders
|
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
|
WO2023278410A1
(en)
|
2021-06-29 |
2023-01-05 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
|
EP4380576A4
(en)
|
2021-08-03 |
2026-04-29 |
Verve Therapeutics Inc |
RNA TARGETED COMPOSITIONS AND ADMINISTRATION METHODS
|
|
US20250188455A1
(en)
*
|
2021-09-02 |
2025-06-12 |
Vanderbilt University |
Lipophilic oligonucleotide conjugates
|
|
EP4401792A4
(en)
|
2021-09-16 |
2025-12-03 |
Avidity Biosciences Inc |
COMPOSITIONS AND METHODS OF TREATMENT OF FACIO-SCAPULO-HUMERAL MUSCULAR DYSTROPHY
|
|
AU2022370009A1
(en)
|
2021-10-22 |
2024-05-16 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
|
WO2023078883A1
(en)
|
2021-11-03 |
2023-05-11 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating apolipoprotein e4 expression
|
|
AU2022384619A1
(en)
|
2021-11-11 |
2024-04-11 |
F. Hoffmann-La Roche Ag |
Pharmaceutical combinations for treatment of hbv
|
|
EP4441224A4
(en)
*
|
2021-12-03 |
2026-03-11 |
Quralis Corp |
Antisense oligonucleotides with modified skeletal chemicals
|
|
CN118434858A
(zh)
|
2021-12-07 |
2024-08-02 |
豪夫迈·罗氏有限公司 |
靶向actl6b的反义寡核苷酸
|
|
CN119095603A
(zh)
|
2021-12-17 |
2024-12-06 |
豪夫迈·罗氏有限公司 |
用于调节rtel1和fubp1的寡核苷酸的组合
|
|
EP4448763A1
(en)
|
2021-12-17 |
2024-10-23 |
F. Hoffmann-La Roche AG |
Oligonucleotide gba agonists
|
|
JP2024547071A
(ja)
|
2021-12-20 |
2024-12-26 |
エフ． ホフマン－ラ ロシュ アーゲー |
トレオース核酸アンチセンスオリゴヌクレオチドおよびその方法
|
|
WO2023141507A1
(en)
|
2022-01-20 |
2023-07-27 |
Genentech, Inc. |
Antisense oligonucleotides for modulating tmem106b expression
|
|
AR128558A1
(es)
|
2022-02-21 |
2024-05-22 |
Hoffmann La Roche |
Oligonucleótido antisentido
|
|
EP4495241A1
(en)
|
2022-03-16 |
2025-01-22 |
Daiichi Sankyo Company, Limited |
Chemically-modified oligonucleotide having rnai activity
|
|
IL315659A
(en)
|
2022-03-16 |
2024-11-01 |
Daiichi Sankyo Co Ltd |
siRNA FOR SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR-2
|
|
JP2025516554A
(ja)
|
2022-05-10 |
2025-05-30 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｃｆｐ－ｅｌｋ１遺伝子間領域を標的とするアンチセンスオリゴヌクレオチド
|
|
PE20250394A1
(es)
|
2022-05-18 |
2025-02-11 |
Hoffmann La Roche |
Oligonucleotidos mejorados que actuan sobre sitios de proteina de union a arn
|
|
EP4282964A1
(en)
*
|
2022-05-23 |
2023-11-29 |
Universitat de Valéncia |
Oligonucleotides conjugated to oleic acid and uses thereof
|
|
WO2023242324A1
(en)
|
2022-06-17 |
2023-12-21 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for targeting progranulin
|
|
EP4332221A1
(en)
|
2022-08-29 |
2024-03-06 |
Roche Innovation Center Copenhagen A/S |
Threose nucleic acid antisense oligonucleotides and methods thereof
|
|
JP2025529283A
(ja)
|
2022-09-06 |
2025-09-04 |
エフ． ホフマン－ラ ロシュ アーゲー |
眼への投与のための二本鎖ｒｎａ分子
|
|
JP2025532127A
(ja)
|
2022-09-23 |
2025-09-29 |
アイオーニス ファーマシューティカルズ， インコーポレーテッド |
Ｍｅｃｐ２発現を低減する化合物及び方法
|
|
IL321025A
(en)
*
|
2022-11-21 |
2025-07-01 |
Pepgen Inc |
Cell-penetrating peptides, conjugates thereof, and methods of their use
|
|
WO2024126654A1
(en)
|
2022-12-14 |
2024-06-20 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting actl6b
|
|
WO2024153586A1
(en)
|
2023-01-16 |
2024-07-25 |
Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement |
Antisense molecules and their uses for the treatment of coronavirus infection, in particular the treatment of covid-19 related to sars-cov-2 infection
|
|
JP2026504911A
(ja)
|
2023-01-19 |
2026-02-10 |
アルトス ラブス，インコーポレーテッド |
臓器移植における再生因子の使用
|
|
JP2026511268A
(ja)
*
|
2023-03-17 |
2026-04-10 |
コラージュ バイオ インコーポレーテッド |
化学修飾ヌクレオチド
|
|
JP2026514403A
(ja)
*
|
2023-03-30 |
2026-05-11 |
ラクティゲン セラピューティクス |
オリゴヌクレオチド送達担体およびその使用方法
|
|
KR20260021596A
(ko)
|
2023-04-05 |
2026-02-13 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Pln 발현을 감소시키는 화합물 및 방법
|
|
CN121263524A
(zh)
|
2023-05-04 |
2026-01-02 |
豪夫迈·罗氏有限公司 |
能够上调葡糖脑苷脂酶表达的寡核苷酸
|
|
TW202508607A
(zh)
*
|
2023-05-19 |
2025-03-01 |
大陸商北京炫景瑞醫藥科技有限公司 |
雙股寡核苷酸及其共軛物和用途
|
|
KR20260026070A
(ko)
|
2023-06-16 |
2026-02-25 |
에프. 호프만-라 로슈 아게 |
Jak1 발현 조절을 위한 이중 가닥 올리고뉴클레오티드
|
|
AU2024323589A1
(en)
|
2023-08-16 |
2026-03-05 |
Les Laboratoires Servier |
Oligonucleotides for modulating kcnt1 expression
|
|
WO2025059511A1
(en)
|
2023-09-15 |
2025-03-20 |
Praxis Precision Medicines, Inc. |
Elsunersen / prax-222 for use in the treatment of scn2a-related disorders
|
|
WO2026006436A1
(en)
|
2024-06-25 |
2026-01-02 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of tar dna binding protein 43 kda (tdp43)
|
|
WO2026024954A2
(en)
|
2024-07-24 |
2026-01-29 |
Altos Labs, Inc. |
Use of regeneration factors in organ transplantation
|
|
EP4711455A1
(en)
|
2024-09-11 |
2026-03-18 |
Aarhus Universitet |
Small artificial rna (smartrna) oligonucleotide for modulating protein expression
|
|
US20260216357A1
(en)
*
|
2024-10-28 |
2026-07-30 |
Atrium Therapeutics, Inc. |
Lipid antibody oligonucleotide conjugates compositions and uses thereof
|
|
WO2026132147A1
(en)
|
2024-12-20 |
2026-06-25 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting downstream of the transcripts 3' terminus
|